




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 31/41, C07D 249/12 C07C 159/00	A1	(11) International Publication Number: WO 89/ 06125 (43) International Publication Date: 13 July 1989 (13.07.89)
(21) International Application Number: PCT/US88/04578 (22) International Filing Date: 21 December 1988 (21.12.88) (31) Priority Application Number: 140,074 (32) Priority Date: 31 December 1987 (31.12.87) (33) Priority Country: US (71) Applicant: SMITHKLINE BECKMAN CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US). (72) Inventors: KRUSE, Lawrence, Ivan ; 33 Firs Walk, Tewin, Hertfordshire AL6 0NY (GB). FINKELSTEIN, Joseph, Alan ; 7549 Brentwood Road, Philadelphia, PA 19151 (US).		(74) Agents: McCARTHY, Mary, E. et al.; Corporate Patents & Trademarks, N160, SmithKline Beckman Corporation, P.O. Box 7929, Philadelphia, PA 19101 (US). (81) Designated States: AU, DK, JP. Published <i>With international search report.</i>

(54) Title: 4-ARALKYL-5-SUBSTITUTED-1,2,4-TRIAZOLE-5-THIOLS

**(57) Abstract**

Disclosed are novel 4-aralkyl-5-substituted-1,2,4-triazole-5-thiols of structure (I), intermediates useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as dopamine- β -hydroxylase inhibitors.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria
AU Australia
BB Barbados
BE Belgium
BG Bulgaria
BJ Benin
BR Brazil
CF Central African Republic
CG Congo
CH Switzerland
CM Cameroon
DE Germany, Federal Republic of
DK Denmark
FI Finland

FR France
GA Gabon
GB United Kingdom
HU Hungary
IT Italy
JP Japan
KP Democratic People's Republic
of Korea
KR Republic of Korea
LI Liechtenstein
LK Sri Lanka
LU Luxembourg
MC Monaco
MG Madagascar

ML Mali
MR Mauritania
MW Malawi
NL Netherlands
NO Norway
RO Romania
SD Sudan
SE Sweden
SN Senegal
SU Soviet Union
TD Chad
TG Togo
US United States of America

1

5

- 1 -

10

4-ARALKYL-5-SUBSTITUTED-1,2,4-TRIAZOLE-5-THIOLS

The present invention relates to novel substituted 4-aralkyl-5-substituted-1,2,4-triazole-3-thiols, processes for their preparation, intermediates
15 useful in their preparation, pharmaceutical compositions containing them and their use in therapy in particular as DBH inhibitors.

Compounds that inhibit DBH activity are well
20 known in the art and include:

(a) 5-alkylpicolinic acids [See, Suda et al., Chem. Pharm. Bull. 17, 2377 (1969); Umezawa et al., Biochem. Pharmacol. 19, 35 (1969); Hidaka et al., Mol. Pharm. 2, 1972 (1973); Miyano et al., Chem. Pharm. Bull. 26, 2328 (1978); Miyano et al., Heterocycles 14, 755 (1980); Claxton et al., Eur. J. Pharmacol. 37, 179 (1976)];

(b) BRL 8242 [See, Claxton et al., Eur. J. Pharmacol. 37, 179 (1976)];

(c) 1-alkylimidazole-2-thiols [See, Hanlon et al., Life Sci. 12, 417 (1973); Fuller et al., Adv. Enzyme Regul. 15 267 (1976)];

35

(d) substituted thioureas [See, Johnson et al., J. Pharmacol. Exp. Ther. 168, 229 (1969)]; and

1 (e) benzyloxamine and benzylhydrazine [See,
Creveling et al., Biochim. Biophys. Acta 64, 125 (1962);
Creveling et al., Biochim. Biophys. Acta 8, 215 (1962);
Van De Schoot et al., J. Pharmacol. Exp. Ther. 141, 74
5 (1963); Bloom, Ann N.Y. Acad. Sci. 107, 878 (1963)].

(f) fusaric acid derivatives and analogues
[See, Runti et al., Il Farmaco Ed. Sci. 36, 260 (1980)]
for example phenylpicolinic acid, 5-(4-chlorobutyl)
10 picolinic acid, substituted amides of fusaric acid and
acids and amides of 5-butydropicolinic acid,
5-aminopicolinic acid, 5-hydrazinopicolinic acid, and
derivatives thereof.

15 (g) Hidaka et al., Molecular Pharmacology, 2,
172-177 (1972) 5-(3,4-dibromobutyl)picolinic acid and
5-(dimethyldithiocarbamoyl)methylpicolinic acid.

(h) Bupicomide, 5-(n-butyl)picolinamide, is
20 reported by Ehrreich et al., "New Antihypertensive Drugs",
Spectrum Publications, 1976, pg. 409-432,


(i) In United States Patent No. 4,532,331 a
series of 1-phenyl and 1-phenylalkylimidazole compounds
25 having a mercapto or alkylthio group in the 2-position are
disclosed.

(j) United States Patent No. 4,487,761
describes several methylpyridine derivatives isolated from
30 the fermentation broth of a strain of Streptovercicillium.

(k) Friedman et al., Psychosomatic Med. 40, 107
(1978), report that patients treated with alpha-methyl-
DOPA, guanethidine, and reserpine, but not propranolol
35 and diuretics, have lowered DBH levels, although the
significance of the observation is uncertain.

- 1 (1) In United States Patent No. 3,448,423 are
disclosed compounds having the formula:

5




10

- in which R^2 and R^3 can be H, and R^1 can be substituted phenyl. The compounds are said to have analgesic, anti-inflammatory and antipyretic properties. Gerbert et al., US Patent 3,915,980, disclose such
15 compounds wherein R^1 can be phenyl or phen(C_{1-3})alkyl, as intermediates to imidazolyl-2-thioalkanoic acid esters.

(m) Iverson, Acta Chem. Scan. 21, 279 (1967) reports compounds having the formula :


20



- 25 wherein R can be $-CO_2H$ or $-CH_2NHC_6H_5$, but does not report pharmaceutical uses for the compounds.

In addition to the foregoing, a number of compounds which are structurally related to those of the
30 present invention are also known, however, no DBH activity has been attributed to them;

35



SUBSTITUTE SHEET

- 1 For example, compounds of the above noted structure in which n is O, Y¹ is hydrogen and Y² is one or more substituents selected from hydrogen, halogen, hydroxy or alkoxy are disclosed in Bany, T. et al. Ann
5 Univ. Mariae Curie-Sklodowska Sect AA, pp. 29-30, 163-169, 1976; Tandon, M. et al. Indian J.Chem. 20B(11):1017-1018, 1981; Shah, M.H. et al. J. Pharm. Sci. 58(11):1398-1401, 1969; Jaiswal, R.K. et al. J. Heterocycl. Chem. 16(3):561-565, 1979; Mazzone, G. et al. Farmaco Ed.Sci.
10 36(3):181-196, 1981; compounds in which n is O, and Y¹ is a 2-methyl or 2-methoxy substituent and Y² is hydrogen, alkyl, alkoxy, hydroxy or halogen are disclosed in Rao, V.R. and Srinivasan, V.R. Symp. Syn. Heterocycl. Compounds Physiol Interest, pp. 137-144, 1964; Shukla, J.S. et al. J.Prakt. Chem. 311(3):523- 526, 1969; Nath, T.G. et al. Indian J. Chem. 15B(4): 341- 346, 1977; compounds in which n is O, Y¹ is a 3-methyl or 3-halo group and Y² is selected from hydrogen, alkyl, alkoxy, halogen or hydroxy are disclosed in Hazzaa, A.A.B. and
20 Shafik, R.M. Egypt J. Pharm. Sci. 19(1-4):201-206, 1978; Nath, T.G. et al. Indian J. Chem. 15B(4): 341-346, 1977; Shukla, J.S. et al. J.Prakt.Chem. 311(3): 523-526, 1969; Srivastava, U. et al. Bokin Bobai 7(9):T414-T417, 1979; compounds in which n is O, Y¹ is a 4-methyl, 4-alkoxy or
25 4-halo group and Y² is hydrogen, alkoxy, hydroxy, halogen or nitro are disclosed in Shukla, J.S. et al. J.Prakt.Chem. 311(3): 523-526, 1969; Tandon, M. et al. Indian J.Chem. 20B(11):1017-1018, 1981; Bhat, A.K. et al. Indian J.Chem. 5(9):397-401, 1967; Bany, T. et al. Ann
30 Univ. Mariae Curie-Sklodowska Sect AA, pp. 29-30, 163-169, 1976; Joshni, K.C. and Mehta, D.S. J.Indian Chem. Soc. 51(6):613-615, 1974; compounds in which n is O, Y¹ is 3,4-methyl or 2,4-methyl and Y² is 3,4,5-methoxy group are disclosed in Jaiswal, R.K. et al. J.Heterocycl.Chem.
35 16(3): 561-565, 1979; compounds in which n is O, Y¹ is a 3,4-chloro and Y² is 2-hydroxy-4-bromo or 4-fluoro are disclosed in Bhat, A.K. et al. Indian J.Chem. 5(9):397-401, 1967; Joshni, K.C. and Mehta, D.S. J.Indian


- 1 Chem. Soc. 51(6):613-615, 1974; and compounds in which n
is 1, Y¹ is hydrogen and Y² is hydrogen, methyl,
methoxy, halogen or NO₂ are disclosed in Vakula, T.R. et
al. Indian J. Chem. 7(6):577-580, 1969. The compounds
5 disclosed in the fore- going references are disclosed as
synthetic intermediates or as antimicrobial agents.

Non-specific, often toxic effects of known DBH
inhibitors have obviated clinical use of these compounds.
10 Fusaric acid, for example, is hepatotoxic. See, for
example, Teresawa et al., Japan Cir. J. 35, 339 (1971) and
references cited therein.

Therefore there is a continuing need for novel
15 compounds that possess DBH inhibitory activity.

Accordingly the present invention provides
compounds of structure (I):

20



(I)

25

in which,

n is 0 to 5;

30 X¹ to X⁵ are any accessible combination of hydrogen,
halogen, C₁₋₆alkyl, C₁₋₆alkoxy, cyano,
nitro, SONH₂, SO₂NH₂, SO₂CH₃,
SO₂CH₂F, SO₂CHF₂, SO₂CF₃, CF₃,
CHO, OH, CH₂OH, CO₂H, or CO₂C_pH_{2p+1}
35 wherein p is 1 to 4;

R¹ is phenyl substituted by X¹ to X⁵, C₁₋₄alkyl,
C₃₋₆cycloalkyl, or an aryl C₁₋₄ alkyl group
substituted by X¹ to X⁵;

SUBSTITUTE SHEET

1 R^2 is hydrogen, C_{1-4} alkyl or $(CH_2)_m-CO_2R^3$;

m is 0 to 5; and

5 R^3 is H or C_{1-4} alkyl;

or pharmaceutically acceptable salts thereof provided that

10 (i) when n is 0, R^2 is hydrogen and X^1 to X^5 are hydrogen, R^1 is other than phenyl or phenyl substituted by OH, C_{1-6} alkoxy, halogen;

15 (ii) when n is 0, R^2 is hydrogen, X^1 is C_{1-6} alkyl or C_{1-6} alkoxy and X^2 to X^5 are hydrogen, R^1 is other than phenyl or phenyl substituted by C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy or halogen;

20 (iii) when n is 0, R^2 is hydrogen, X^2 is C_{1-6} alkyl or halogen and X^1 and X^3 to X^5 are hydrogen, R^1 is other than phenyl or phenyl substituted by C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy or halogen;


25 (iv) when n is 0, R^2 is hydrogen, X^1 , X^2 and X^4 , X^5 are hydrogen and X^3 is C_{1-6} alkyl, halogen or C_{1-6} alkoxy, R^1 is other than phenyl or phenyl substituted by C_{1-6} alkoxy, hydroxy, halogen or nitro;

30 (v) when n is 0, R^2 is hydrogen, X^4 and X^5 are hydrogen, X^1 and X^2 are each hydrogen or C_{1-6} alkyl and X^3 is C_{1-6} alkyl, R^1 is other than a phenyl

- 1 group substituted by three C₁₋₆alkoxy groups;
- 5 (iv) when n is 0, R² is hydrogen, X¹, X⁴ and X⁵ are hydrogen and X² and X³ are halogen, R¹ is other than a phenyl group substituted by hydroxy or halogen; and
- 10 (vii) when n is 1, R² is hydrogen and X¹ to X⁵ are all hydrogen, R¹ is other than phenyl or a phenyl group substituted by C₁₋₆alkyl, C₁₋₆alkoxy, halogen or NO₂.

15 As used herein "accessible combination" means any combination of the substituents that is available by chemical synthesis and is stable.

It will be appreciated that when R is hydrogen
20 Structure (I) covers the tautomeric forms thereof that is compounds of structure (Ia)



Suitably n is 0 to 5, preferably 0 or 1, most
30 preferably 1.

Suitably X¹ to X⁵ are all hydrogen. More suitably at least one of X¹ to X⁵ is halogen and the others are hydrogen. Preferably, X² or X⁴ is halogen
35 or X⁴ and X² are halogen and X¹, X³ and X⁵ are all hydrogen. More preferably X² and X⁴ are halogen, X¹ and X⁵ are hydrogen and X³ is C₁₋₆alkoxy.

- 1 Most preferably X^2 and X^4 are fluorine; X^1 and X^5 are hydrogen and X^3 is methoxy.

5 Suitably R^1 is phenyl. Preferably R^1 is a substituted phenyl group. Most preferably R^1 is a phenyl group substituted by a single substituent, in particular a C_{1-6} alkyl group, such as t-butyl in the 4-position of the ring.

- 10 It is to be noted that C_{1-6} alkyl groups either alone or as part of another group (e.g. aryl C_{1-6} alkyl) can be straight or branched.


Particular compounds of this invention include:

15 3-mercapto-4-benzyl-5-phenyl-1,2,4-triazole,
3-mercapto-4-methyl-5-phenyl-1,2,4-triazole,
3-mercapto-4-(3,5-difluorobenzyl)-5-phenyl-1,2,4-triazole,
3-mercapto-4-(3,5-difluoro-4-methoxybenzyl)-5-phenyl-1,2,4-triazole,
20 3-mercapto-4-(3,5-difluoro-4-hydroxybenzyl)-5-phenyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-triazole,
3-mercapto-4-(3,5-difluorobenzyl)-5-(4-t-butylphenyl)-1,2,4-triazole,
25 3-mercapto-4-phenyl-5-(4-t-butylphenyl)-1,2,4-triazole,
3-mercapto-4-(4-chlorophenyl)-5-(4-t-butylphenyl)-1,2,4-triazole,
3-mercapto-4-(4-bromophenyl)-5-(4-t-butylphenyl)-1,2,4-triazole,
30 3-mercapto-4-(4-fluorophenyl)-5-(4-t-butylphenyl)-1,2,4-triazole,
3-mercapto-4-(3-phenylpropyl)-5-(4-t-butylphenyl)-1,2,4-triazole,
35 3-mercapto-4-(3-phenylethyl)-5-(4-t-butylphenyl)-1,2,4-triazole,
3-mercapto-4-[3-(3,5-difluorophenyl)propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,

SUBSTITUTE SHEET

- 1 3-mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)-
propyl]- 5-(4-t-butylphenyl)-1,2,4-triazole,
3-mercapto-4-[3-(3,5-difluoro-4-hydroxyphenyl)-
propyl]- 5-(4-t-butylphenyl)-1,2,4-triazole,
5 3-mercapto-4-benzyl-5-methyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-n-propyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-n-pentyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-n-nonyl-1,2,4-triazole,
10 3-mercapto-4-benzyl-5-cyclohexyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-t-butyl-1,2,4-triazole,
3-mercapto-4,5-dibenzyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-phenethyl-1,2,4-triazole,
3-mercapto-4-benzyl-5-(4-methoxyphenyl)-1,2,4-
15 triazole,
3-mercapto-4-benzyl-5-(3,4,5-trimethoxyphenyl)-
1,2,4-triazole,
3-mercapto-4-benzyl-5-(4-chlorophenyl)-1,2,4-
triazole,
20 3-mercapto-4-benzyl-5-(4-bromophenyl)-1,2,4-
triazole, and
3-mercapto-4-benzyl-5-(3-bromophenyl)-1,2,4-
triazole.

- 25 A further aspect of the invention provides a
process for preparation of compounds of structure (I) and
pharmaceutically acceptable salts thereof which comprises
cyclization of a compound of structure (II)



in which X^1 to X^5 are any accessible combination of
hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano,

- 1 nitro, SONH_2 , SO_2NH_2 , SO_2CH_3 , $\text{SO}_2\text{CH}_2\text{F}$,
 SO_2CHF_2 , SO_2CF_3 , CF_3 , CHO , $\text{CH}_2\text{OC}_{1-6}\text{alkyl}$, or
 $\text{CO}_2\text{C}_{1-6}\text{alkyl}$; and n and R' are as described for
structure (I); and optionally thereafter converting a
5 group X^1 to X^5 into a OH , CH_2OH or CO_2H group,
converting a compound of structure (I) in which R^2 is
hydrogen to one in which R is $\text{C}_{1-4}\text{alkyl}$ or
 $\text{C}_{1-4}\text{alkanoic acid}$ and optionally forming a
pharmaceutically acceptable salt.


10

The cyclization is carried out in a suitable
solvent in the presence of a base. In particular the
reaction is carried out in ethanol in the presence of
sodium ethoxide as the base.

15

Compounds of structure (II) are prepared by
reaction of a compound of structure (III) and a compound
of structure (IV)

20



(III)



(IV)

25

in which X^1 to X^5 , n and R' are as described for
structure (II).


30

The reaction is carried out in an inert solvent
at elevated temperature. Suitable solvents include for
example $\text{C}_{1-6}\text{alkanols}$ such as methanol or ethanol,
tetrahydrofuran and ethyl acetate; preferably ethanol.

35

Compounds of structures (III) and (IV) are
prepared by methods analogous to those known in the art
or are available commercially, for example, compounds of

1 structure (III) are prepared from compounds of structure
(V)



10

in which X^1 to X^5 are as described for structure (II)
and A is CN, by reduction with, for example, hydrogen and
ammonia in the presence of a Raney alloy to form a
15 compound of structure (V) in which A is CH_2NH_2 ;
followed by reaction with, for example, thiophosgene in
the presence of a base to form the desired compounds of
structure (III).

20 It is to be noted that as an alternative to
preparation and isolation of intermediate (II) by reaction
of a compound of structures (III) and (IV) as hereinabove
described, the compounds of structures (III) and (IV) may
be reacted together and the product cyclized in a single
25 step to form the desired compounds of structure (I).
Suitable conditions include for example, heating the
compounds (III) and (IV) optionally in the presence of a
solvent, at elevated temperature for a suitable time,
followed by addition of a suitable base, for example,
30 sodium ethoxide in ethanol to effect the cyclization.

Compounds of the invention in which R^2 is
 C_{1-4} alkyl are prepared by alkylating the corresponding
compound of structure (I) where R^2 is hydrogen with an
35 alkyl halide in the presence of a base, for example,
methyl iodide in methanol in the presence of potassium
carbonate, by procedures known to those skilled in the
art. Other alkyl reagents such as methyl bromide or

SUBSTITUTE SHEET

1 dimethyl sulphate, in appropriate solvents in the presence
of a base, can be substituted for methyl iodide. Further,
the compounds of structure (I) in which R^2 is an alkyl
group other than methyl are prepared by substituting an
5 alkyl halide such as butyl iodide, for the methyl halide
to yield the desired substituted 4-alkyl-5-substituted-
1,2,4-triazole-3-thiols of the invention.

Compounds of structure (I) in which R^3 is
10 C_{1-4} alkyl are prepared by reacting the corresponding
compound of structure (I) where R is hydrogen with a
haloalkanoate ester in the presence of base by procedures
known to those skilled in the art. Compounds of structure
(I) in which R^3 is hydrogen are prepared by mild acid or
15 base hydrolysis of structure (I) compounds in which R^3
is C_{1-4} alkyl by procedures known to those skilled in the
art.

Pharmaceutically acceptable acid addition salts
20 of compounds of the invention are formed with appropriate
strong or moderately strong organic or inorganic acids by
methods known in the art. For example, the base is
reacted with a suitable inorganic or organic acid in an
aqueous miscible solvent such as ethanol with isolation of
25 the salt by removing the solvent or in an aqueous
immiscible solvent when the acid is soluble therein, such
as ethyl ether or chloroform, with the desired salt
separating directly or isolated by removing the solvent.


30 Exemplary of the salts which are included in
this invention include maleate, fumarate, lactate,
oxalate, methanesulfonate, ethanesulfonate,
benzenesulfonate, tartrate, citrate, hydrochloride,
hydrobromide, sulfate, phosphate, quinate, and nitrate
35 salts.

Pharmaceutically acceptable base addition salts
of compounds of the invention containing an acidic group

SUBSTITUTE SHEET

- 1 (R is $(\text{CH}_2)_m\text{-CO}_2\text{R}^3$ and R^3 is H) are prepared by
 known methods from organic and inorganic bases including
 nontoxic alkali metal and alkaline earth bases, for
 example, calcium, sodium, and potassium hydroxide;
 5 ammonium hydroxide, and nontoxic organic bases such as
 trimethylamine, triethylamine, propylamine, butylamine,
 piperazine, and (trihydroxymethyl)methylamine.

The present invention also provides a method of
 10 inhibiting DBH which comprises administering to a
 mammal, including a human, an effective amount of a
 compound of structure (Ib).



20

in which,

n is 0 to 5;

25

X^1 to X^5 are any accessible combination of hydrogen,
 halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano,
 nitro, SONH_2 , SO_2NH_2 , SO_2CH_3 ,
 $\text{SO}_2\text{CH}_2\text{F}$, SO_2CHF_2 , SO_2CH_3 , CF_3 ,
 30 CHO , OH , CH_2OH , CO_2H , or $\text{CO}_2\text{C}_p\text{H}_{2p+1}$
 wherein p is 1 to 4;

35

R^1 is phenyl substituted by the groups X^1 to X^5 ,
 C_{1-4} alkyl, C_{3-6} cycloalkyl, or an
 aryl C_{1-4} alkyl group substituted by X^1 to
 X^5 as described above;

SUBSTITUTE SHEET

1 R^2 is hydrogen, C_{1-4} alkyl or
(CH_2)_m-CO₂R³;

m is 0 to 5; and

5 R^3 is H or C_{1-4} alkyl;

or a pharmaceutically acceptable salt thereof.

10 Because the compounds of structure (I) inhibit
DBH activity, they have therapeutic value as diuretic,
natriuretic, cardiogenic, antihypertensive, and
vasodilatoragents, as well as antiulcerogenic and
anti-Parkinson agents. Listed in Table III are the
15 compounds of the invention that were tested for in vitro
DBH inhibition by a standard procedure for assaying
conversion of tyramine to octopamine in the presence of
DBH. J.J. Pisano, et al., Biochim. Biophys. Acta, 43,
566-568 (1960). Octopamine was assayed following sodium
20 periodate oxidation to p-hydroxybenzaldehyde by measuring
spectrophotometric absorbance at 330 nm. In Table III,
inhibition is given in micromolar concentration of
compound at which DBH activity was halved (IC₅₀). By
this test, fusaric acid had an IC₅₀ of 0.8 micromolar.

25

Table I

	<u>Example</u>	<u>DBH IC₅₀</u> <u>(μM)</u>
30	2	1.2 x 10 ⁻⁵
	4	1.1 x 10 ⁻⁴
	8	7.4 x 10 ⁻⁶
	12	5.7 x 10 ⁻⁶
35	13	8.3 x 10 ⁻⁶
	15	6.4 x 10 ⁻⁷
	17	5.0 x 10 ⁻⁷
	18	7.7 x 10 ⁻⁷

SUBSTITUTE SHEET

1	19	4.6×10^{-7}
	21	3.2×10^{-7}
	23	3.8×10^{-7}
	25	4.3×10^{-7}
5	26	7.8×10^{-7}
	28	3.0×10^{-7}
	30	3.0×10^{-7}
	31	1.25×10^{-6}
	32	2.1×10^{-5}
10	33	4.6×10^{-5}
	34	9.0×10^{-6}
	35	1.6×10^{-6}
	36	5.5×10^{-7}
	37	1.5×10^{-5}
15	40	1.1×10^{-4}
	41	2.3×10^{-5}
	43	5.9×10^{-6}
	44	1.1×10^{-6}
	45	2.1×10^{-5}
20	46	2.8×10^{-6}
	47	1.8×10^{-6}
	48	1.6×10^{-6}

Further, spontaneously hypertensive rats were treated with a suspension or solution of 3-mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole at a dose of 50 mg/kg orally, and mean arterial blood pressure was monitored for 260 minutes using indwelling cannulae in the tail arteries. When compared to vehicle-treated controls, animals treated with the compounds of the invention exhibited significant blood pressure reductions within approximately 30 minutes after treatment. Maximal blood pressure reduction was approximately 10 to 35 mm Hg.

The present invention thus also provides a method of treatment to produce lower blood pressure in a mammal, including a human, that comprises administering to a mammal an effective amount of structure (Ib).

SUBSTITUTE SHEET

1 In the methods of the present invention the
compounds of structure (Ib) usually are administered in a
standard pharmaceutical composition. The present
invention therefore provides in a further aspect
5 pharmaceutical compositions comprising a compound of
structure (Ib) or a pharmaceutically salt thereof and a
pharmaceutically acceptable carrier. Such compositions
include those suitable for administration via an
appropriate route known to those skilled in the art for
10 example, orally, parenterally, transdermally, rectally,
via inhalation or via buccal administration.

 The compounds of structure (Ib) and their
pharmaceutically acceptable salts which are active when
15 given orally can be formulated as tablets, capsules,
lozenges and liquids, for example, syrups, suspensions or
emulsions.

 A liquid formulation generally will consist of a
20 suspension or solution of the compound or pharmaceutically
acceptable salt in a suitable liquid carrier(s) for
example, ethanol, glycerine, sorbitol, non-aqueous
solvent, for example polyethylene glycol, oils, or water
with a suspending agent, preservative surfactant, wetting
25 agent, flavouring or colouring agent.

 Alternatively, a liquid formulation is prepared
from a reconstitutable powder. For example a powder
containing active compound, suspending agent, sucrose and
30 a sweetener is reconstituted with water to form a
suspension; and a syrup is prepared from a powder
containing active ingredient, sucrose and a sweetener.

 A composition in the form of a tablet is
35 prepared using any suitable pharmaceutical carrier(s)
routinely used for preparing solid formulations. Examples
of such carriers include magnesium stearate, starch,
lactose, sucrose, cellulose and binders, for example,

SUBSTITUTE SHEET

1 polyvinyl, pyrrolidone. The tablet optionally is provided
with a color film coating, or color included as part of
the carrier(s). In addition, acting compound can be
formulated in a controlled release dosage form such as a
5 tablet comprising a hydrophilic or hydrophobic matrix.

A composition in the form of a capsule is
prepared using routine encapsulation procedures. For
example, pellets containing active ingredient are prepared
10 using standard carriers and then filled into a hard
gelatin capsule; alternatively, a dispersion or
suspension is prepared using any suitable pharmaceutical
carrier(s), for example aqueous gums, celluloses,
silicates or oils and the dispersion or suspension then
15 filled into a soft gelatin capsule.

Typical parenteral compositions consist of a
solution or suspension of the compound or pharmaceutically
acceptable salt in a sterile aqueous carrier or
20 parenterally acceptable oil, for example polyethylene
glycol, polyvinyl pyrrolidone, lecithin, arachis oil or
sesame oil. Alternatively, the solution can be
lyophilized and then reconstituted with a suitable solvent
just prior to administration.

25 A typical suppository formulation comprises a
compound of structure (Ib) or a pharmaceutically
acceptable salt thereof which is active when administered
in this way, with a binding and/or lubricating agent such
30 as polymeric glycols, gelatins or cocoa butter or other
low melting vegetable or synthetic waxes or fats.

Compounds of structure (Ib) and their
pharmaceutically acceptable addition salts which are
35 active on topical administration can be formulated as
transdermal compositions. Such compositions include, for
example, a backing, active compound reservoir, a control
membrane, liner and contact adhesive.

SUBSTITUTE SHEET

1 Typical compositions for inhalation are in the
form of a solution, suspension or emulsion that may be
administered in the form of an aerosol using a
conventional propellant such as dichlorodifluoromethane or
5 trichlorofluoromethane.

 Preferably the composition is in an appropriate
unit dosage form. Each dosage unit for oral
administration contains preferably from 1 to 250 mg (and
10 for parenteral administration contains preferably from 0.1
to 25 mg) of a compound of the structure (Ib) or a
pharmaceutically acceptable salt thereof calculated as the
free acid or base.

15 The daily dosage regimen for an adult patient
may be, for example, an oral dose of between 1 mg and 1000
mg, preferably between 1 mg and 250 mg, or an intravenous,
subcutaneous, or intramuscular dose of between 0.1 mg and
100 mg, preferably between 0.1 mg and 25 mg, of the
20 compound of the structure (Ib) or a pharmaceutically
acceptable salt thereof calculated as the free base, the
compound being administered 1 to 4 or more times per day.
Suitably the compounds are administered for a period of
continuous therapy, for example for a week or more. In
25 addition, the compounds of this invention may be
co-administered with other pharmaceutically active
compounds, for example in combination, concurrently or
sequentially.

30 The following Examples illustrate the
invention. Temperatures are recorded in degrees
centigrade.

35

SUBSTITUTE SHEET

1

Example 11-Benzoyl-4-benzylthiosemicarbazide

5 Benzyl isothiocyanate (6.63 ml, 0.05 mole) was added to a suspension of benzoylhydrazine (6.81 g, 0.05 mole) in ethanol (70 ml) and the mixture was heated at 50-60°C for 30 minutes. The mixture was diluted with ethanol (30 ml), cooled in ice and the solid was
10 filtered. The solid was then triturated with hot ethanol (200 ml), cooled in ice and the product was filtered to give a solid melting at 188-190°C (10.2 g, 71%).

Example 2

15

3-Mercapto-4-benzyl-5-phenyl-1,2,4-triazole

 1-Benzoyl-4-benzylthiosemicarbazide (5.0 g, 0.0175 mole) was added to a solution of sodium ethoxide
20 [from sodium (0.81 g, 0.035 mole) in ethanol (70 ml)] and the solution was heated at reflux for 16 hours. The solvent was removed under vacuum and the residue was dissolved in water (100 ml), cooled in ice and acidified with 10% hydrochloric acid. The product was filtered,
25 recrystallized from ethanol and dried at 50°C to give a solid melting at 184-185°C (3.82 g, 82%).

Example 3

30

1-Benzoyl-4-methylthiosemicarbazide

 Following the method of Example 1, methylisothio- cyanate (3.66 g, 0.05 mole) and
35 benzoylhydrazine (6.81 g, 0.05 mole) gave a solid melting at 188.5-190.5°C (9.71 g, 92%).

1

Example 43-Mercapto-4-methyl-5-phenyl-1,2,4-triazole

5

Following the method of Example 2, 1-benzoyl-4-methylthiosemicarbazide (9.0 g, 0.043 mole) and sodium ethoxide [from sodium (1.98 g, 0.086 mole) in ethanol (200 ml)] gave the product which was recrystallized from ethanol with melting point 165-166°C (7.03 g, 85%).

10

Example 53,5-Difluorobenzylamine

15

A slurry of Raney nickel in methanol was added to a solution of 3,5-difluorobenzonitrile (6.5 g, 0.0467 mole) in methanol (100 ml) saturated with ammonia and the mixture was hydrogenated for 2.25 hours at 50 lbs pressure. The solution was decanted from the catalyst and the catalyst washed four times with methanol and decanted. The combined decanted solvent was evaporated and the residue dissolved in ethyl acetate and extracted twice with 1N hydrochloric acid (50 ml). The acid solution was made basic with 10% sodium hydroxide and extracted with three portions of ethyl acetate. The ethyl acetate was washed with water, brine, dried over sodium sulfate and the solvent removed to give the product as an oil (6.2 g, 93%).

30

Example 63,5-Difluorobenzylisothiocyanate

A solution of 3,5-difluorobenzylamine (6.2 g, 0.043 mole) and triethylamine (13.3 ml, 0.0953 mole) in dry tetrahydrofuran (35 ml) was added dropwise to thiophosgene (3.6 ml, 0.048 mole) in dry tetrahydrofuran (30 ml) with ice cooling. After stirring at 25°C for 2

1 hours the mixture was diluted with ether and filtered.
The filtrate was treated twice with activated carbon,
filtered and the solvent was removed at reduced
pressure. The residue was distilled under vacuum to give
5 the product as an oil (4.58 g, 57%).

Example 7

1-Benzoyl-4-(3,5-difluorobenzyl)thiosemicarbazide

10

Following the method of Example 1,
3,5-difluoro- benzylisothiocyanate (4.50 g, 0.0243 mole)
and benzoylhydrazine (3.31 g, 0.0243 mole) gave a solid
melting at 182-190°C (5.80 g, 74%).

15

Example 8

3-Mercapto-4-(3,5-difluorobenzyl)-5-phenyl-1,2,4-triazole

20

Following the method of Example 2, 1-benzoyl-4-
(3,5-difluorobenzyl)thiosemicarbazide (5.46 g, 0.017 mole)
and sodium ethoxide [from sodium (0.781 g, 0.034 mole) in
ethanol (110 ml)] gave the product which was
recrystallized from ethanol with melting point 188-189°C
25 (4.28 g, 83%).

Example 9

3,5-Difluoro-4-methoxybenzylamine

30

Following the method of Example 5,
3,5-difluoro-4- methoxybenzonitrile (8.0 g, 0.0473 mole)
gave the product as an oil (8.0 g, 98%).

35

SUBSTITUTE SHEET

1

Example 103,5-Difluoro-4-methoxybenzylisothiocyanate

5

Following the method of Example 6,
3,5-difluoro-4- methoxybenzyl amine (8.0 g, 0.046 mole)
gave the product as an oil (3.7 g, 37%).

Example 11

10

1-Benzoyl-4-(3,5-difluoro-4-methoxybenzyl)thiosemicarbazide

Following the method of Example 1,
3,5-difluoro-4- methoxybenzylisothiocyanate (3.70 g,
15 0.0172 mole) and benzoylhydrazine (2.34 g, 0.0172 mole)
gave a solid which recrystallized from ethanol with a
melting point of 165-167°C (5.80 g, 74%).

Example 12

20

3-Mercapto-4-(3,5-difluoro-4-methoxybenzyl)-5-phenyl-1,2,4-triazole

Following the method of Example 2,
25 1-benzoyl-4-(3,5-difluoro-4-methoxybenzyl)thiosemicarbazide
(3.30 g, 9.4 mmole) and sodium ethoxide [from sodium
(0.432 g, 18.8 mmole) in ethanol (50 ml)] gave the product
which was recrystallized from ethanol with melting point
177-178°C (2.83 g, 90%).

30

Example 133-Mercapto-4-(3,5-difluoro-4-hydroxybenzyl)-5-phenyl-1,2,4-triazole

35

Boron tribromide (12.4 ml of 40% methylene
chloride solution, 19.7 mmole) was added dropwise to a
suspension of 3-mercapto-4-(3,5-difluoro-4-methoxybenzyl)-

1 5-phenyl-1,2,4-triazole and the mixture was stirred for 16
hours at 25°C. The reaction was quenched in ice/ethyl
acetate and the ethyl acetate fraction was washed with
brine and dried with magnesium sulfate. The mixture was
5 filtered and the solvent was removed under vacuum to give
a solid which was recrystallized twice from ethanol to
give a solid melting at 192-193°C (1.25 g, 60%).

Example 14

10

1-(4-t-Butylbenzoyl)-4-benzylthiosemicarbazide

Following the method of Example 1,
benzylisothiocyanate (1.38 ml, 0.0104 mole) and
15 4-t-butylbenzoyl- hydrazine (2.00 g, 0.0104 mole) gave a
solid melting at 185-186°C (2.10 g, 59%).

Example 15

20 3-Mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-triazole

Following the method of Example 2,
1-(4-t-butyl- benzoyl)-4-benzylthiosemicarbazide (2.03 g,
5.94 mmole) and sodium ethoxide [from sodium (0.273 g,
25 11.9 mmole) in ethanol (30 ml)] gave the product which was
recrystallized from ethanol/water with melting point
191-193°C (1.64 g, 85%).

Example 16

30

1-(4-t-Butylbenzoyl)-4-(3,5-difluorobenzyl)thiosemicarbazide

Following the method of Example 1, 3,5-
35 difluorobenzylisothiocyanate (2.02 g, 0.0109 mole) and
4-t-butylbenzoyl- hydrazine (2.1 g, 0.0109 mole) gave a
solid melting at 198-199°C (3.57 g, 87%).

1

Example 173-Mercapto-4-(3,5-difluorobenzyl)-5-(4-t-butylphenyl)-1,2,4-triazole

5

Following the method of Example 2, 1-(4-t-butylbenzoyl)-4-(3,5-difluorobenzyl)thiosemicarbazide (3.45 g, 9.14 mmole) and sodium ethoxide [from sodium (0.420 g, 18.3 mmole in ethanol (50 ml))] gave the product which was
10 recrystallized from ethanol with melting point 187-188°C (2.15 g, 65%).

Example 1815 3-Mercapto-4-phenyl-5-(4-t-butylphenyl)-1,2,4-triazole

Phenylisothiocyanate (2.40 ml, 0.02 mole) was added to a solution of 4-t-butylbenzoylhydrazine (3.85 g, 0.02 mole) and the solution was heated under reflux for
20 one hour. A solution of sodium ethoxide [from sodium (0.92 g, 0.04 mole) in ethanol (25 ml)] was added and the solution was heated under reflux for 17 hours. Additional sodium (0.5 g) was added and the solution was heated under reflux for 24 hours. The reaction mixture was cooled in
25 ice, acidified with 10% hydrochloric acid and the product was filtered. The solid was then triturated with a mixture of hot methanol/ethanol, cooled in ice and the product was filtered and dried with melting point 274-275°C (3.97 g, 64%).

30

Example 193-Mercapto-4-(3-chlorophenyl)-5-(4-t-butylphenyl)-1,2,4-triazole

35

Following the method of Example 18, 3-chlorophenyl- isothiocyanate (2.54 g, 0.015 mole), 4-t-butylbenzoylhydrazine (2.88 g, 0.015 mole) and sodium

1 (1.38 g, 0.06 mole) gave the crude product which was
contaminated with starting material. The solid was
suspended in ethanol and 10% sodium hydroxide (8 ml) was
added and the solution was heated under reflux for 17
5 hours. The reaction mixture was cooled in ice and
acidified with 10% hydrochloric acid. The product was
filtered, recrystallized from ethanol/methylene chloride
and dried to give a solid with a melting point of
250-251°C (2.25 g, 44%).

10

Example 20

1-(4-t-Butylbenzoyl)-4-bromophenylthiosemicarbazide

15 Following the method of Example 1,
4-bromophenyl- isothiocyanate (3.21 g, 0.015 mole) and
4-t-butylbenzoyl- hydrazine (2.88 g, 0.015 mole) gave a
solid (5.42 g, 89%).

20

Example 21

3-Mercapto-4-(4-bromophenyl)-5-(4-t-butylphenyl)-1,2,4-
triazole

25 A solution of sodium ethoxide [from sodium
(0.566 g, 0.0246 mole) in ethanol (20 ml)] was added to a
suspension of 1-(4-t-butylbenzoyl)-4-bromophenylthiosemi-
carbazide (2.5 g, 6.15 mmole) and the mixture was heated
under reflux for 17 hours. A 10% sodium hydroxide
30 solution (15 ml) was added and the mixture was heated
under reflux for an additional 24 hours. The reaction
mixture was cooled in ice and acidified with 10%
hydrochloric acid. The product was filtered,
recrystallized from methanol/methylene chloride and dried
35 to give a solid with a melting point of 256-258°C (1.48 g,
62%).

SUBSTITUTE SHEET

1

Example 221-(4-t-Butylbenzoyl)-4-fluorophenylthiosemicarbazide

5

Following the method of Example 1,
4-fluorophenyl- isothiocyanate (2.30 g, 0.015 mole) and
4-t-butylbenzoyl- hydrazine (2.88 g, 0.015 mole) gave a
solid (5.58 g, 100%).

10

Example 233-Mercapto-4-(4-fluorophenyl)-5-(4-t-butylphenyl)-1,2,4-
triazole

15

A 10% sodium hydroxide solution (15 ml) was
added to a suspension of 1-(4-t-butylbenzoyl)-4-fluoro-
phenylthiosemicarbazide (2.5 g, 7.2 mmole) in ethanol and
the mixture was heated under reflux for 17 hours. The
reaction mixture was cooled in ice and acidified with 10%
20 hydrochloric acid. The product was filtered,
recrystallized from ethyl acetate/hexane and dried to give
a solid with a melting point of 228-242°C (1.21 g, 51%).

Example 24

25

3-Phenylpropylisothiocyanate

Following the method of Example 6,
3-phenylpropyl- amine (6.76 g, 0.05 mole), thiophosgene
30 (4.19 ml, 0.055 mole and triethylamine (15.4 ml, 0.11
mole) gave the product as an oil (6.79 g, 77%).

Example 2535 3-Mercapto-4-(3-phenylpropyl)-5-(4-t-butylphenyl)-1,2,4-
triazole

Following the method of Example 1,
3-phenylpropylisothiocyanate (2.03 g, 11.4 mmole) and

SUBSTITUTE SHEET

1 4-t-butylbenzoyl- hydrazine (2.20 g, 11.4 mmole) gave
1-(4-t-butylbenzoyl)- 4-(3-phenylpropyl)thiosemicarbazide
which was added directly as an ethanol suspension to a
solution of sodium ethoxide [from sodium (0.526 g, 22.9
5 mmole) in ethanol (40 ml)] following the method of Example
2. The product was recrystallized twice from
ethanol/water to give a solid with a melting point
153-154°C (2.99 g, 76%).

10

Example 263-Mercapto-4-(2-phenylethyl-5-(4-t-butylphenyl)-1,2,4-
triazole

15 Phenethylisothiocyanate (2.24 ml, 0.015 mole)
was added to a solution of 4-t-butylbenzoylhydrazine (2.88
g, 0.015 mole) in ethanol (40 ml) and the mixture was
heated under reflux for 2 hours. A solution of sodium
ethoxide [from sodium (1.03 g, 0.045 mole) in ethanol (25
20 ml)] was added and the mixture was heated under reflux for
17 hours. The reaction mixture was cooled in ice and
acidified with 10% hydrochloric acid. The product was
filtered, recrystallized from ethanol/hexane and dried to
give a solid melting at 153-154°C (3.95 g, 78%).

25

Example 273-(3,5-Difluorophenyl)propylisothiocyanate

30 Following the method of Example 6,
3-(3,5-difluorophenyl)propylamine (4.94 g, 0.0289 mole),
thiophosgene (2.242 ml, 0.0317 mole) and triethylamine
(8.8 ml, 0.0635 mole) gave the product which was purified
by flash silica chromatography to give an oil (4.30 g,
35 70%).

SUBSTITUTE SHEET

1

Example 28

3-Mercapto-4-[3-(3,5-difluorophenyl)propyl]-5-(4-t-butylphenyl)-1,2,4-triazole

5

3-(3,5-Difluorophenyl)propylisothiocyanate (2.13 g, 0.010 mole) was added to a solution of 4-t-butylbenzoylhydrazine (1.92 g, 0.010 mole) in ethanol (40 ml) and the mixture was heated under reflux for 3 hours. A solution of sodium ethoxide [from sodium (0.460 g, 0.02 mole) in ethanol (20 ml)] was added and the mixture was treated under reflux for 17 hours. The solvent was removed under vacuum and the residue was dissolved in water. The reaction mixture was cooled in ice and acidified with 10% hydrochloric acid to give a sticky solid. The aqueous solution was decanted and the solid was triturated with ethanol, filtered and recrystallized from ethanol/hexane and dried to give a solid melting at 123-124°C (0.940 g, 24%).

20

Example 29

3-(3,5-Difluoro-4-methoxyphenyl)propylisothiocyanate

25

Following the method of Example 6, 3-(3,5-difluoro-4-methoxyphenyl)propylamine (9.03 g, 0.0448 mole), thiophosgene (3.76 ml, 0.0493 mole) and triethylamine (13.7 ml, 0.0985 mole) gave the product which was purified by flash silica chromatography to give an oil (7.30 g, 67%).

30

Example 30

3-Mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)propyl]-5-(4-t-butylphenyl)-1,2,4-triazole

35

3-(3,5-Difluoro-4-methoxyphenyl)propylisothiocyanate (7.3 g, 0.03 mole) was added to a solution of

1 4-t-butylbenzoylhydrazine (5.77 g, 0.03 mole) in ethanol
(70 ml) and the mixture was heated under reflux for 2
hours. A solution of sodium ethoxide [from sodium
(1.38 g, 0.06 mole) in ethanol (45 ml)] was added and the
5 mixture was heated under reflux for 17 hours. The solvent
was removed under vacuum and the residue was dissolved in
water. The reaction mixture was cooled in ice and
acidified with 10% hydrochloric acid to give a thick oil.
The aqueous solution was decanted and the oil was
10 dissolved in ethanol and the solvent was removed under
vacuum. The residue was dissolved in hexane/ethyl acetate
(1:1) and purified by flash silica chromatography followed
by recrystallisation from ethyl acetate/hexane to give a
solid melting at 173.5-174.5°C (6.53 g, 52%).

15

Example 31

3-Mercapto-4-[3-(3,5-difluoro-4-hydroxyphenyl)propyl]-
5-(4-t-butylphenyl)-1,2,4-triazole

20

Boron tribromide (240 ml of 40% methylene
chloride solution, 38.3 mmole) was added dropwise to a
solution of 3-mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)-
propyl-5-(4-t-butylphenyl)-1,2,4-triazole and the mixture
25 was stirred for 16 hours at 25°C and at 35°C for 4 hours
followed by an additional 16 hours at 25°C. The reaction
was quenched in ice/ethyl acetate and the aqueous solution
was extracted an additional 2 time with ethyl acetate.
The combined ethyl acetate extracts were washed with
30 dilute sodium bicarbonate, water and brine and dried with
sodium sulfate. The solvent was removed under vacuum and
the residue was dissolved in methylene chloride/methanol
(19:1) and purified by flash silica chromatography to
give a solid melting at 159-160°C (1.72 g, 33%).

35

SUBSTITUTE SHEET

1 Example 323-Mercapto-4-benzyl-5-methyl-1,2,4-triazole

5 Following the method of Example 18, benzyl
isothiocyanate (3.32 ml, 0.025 mole), acethydrazide
(1.95 g, 0.025 mole), and sodium ethoxide [from sodium
(1.15 g, 0.05 mole) in ethanol (45 ml)] gave the product
after removing the ethanol under vacuum, diluting the
10 residue with water and acidifying with 10% hydrochloric
acid. The crude product was recrystallized from ethanol
to give a solid with melting point 158-160°C (1.95 g, 38%).

Example 3315 3-Mercapto-4-benzyl-5-n-propyl-1,2,4-triazole

Following the method of Example 18, benzyl
isothiocyanate (3.32 ml, 0.025 mole), n-butyric acid
20 hydrazide (2.55 g, 0.025 mole), and sodium ethoxide [from
sodium (1.15 g, 0.05 mole) in ethanol (40 ml)] gave the
product after removing the ethanol under vacuum, diluting
the residue with water and acidifying with 10%
hydrochloric acid. The crude product was recrystallized
25 twice from ethanol/hexane to give a solid with melting
point 127.5-128.5°C (3.08 g, 53%).

Example 3430 3-Mercapto-4-benzyl-5-n-pentyl-1,2,4-triazole

Following the method of Example 18, benzyl
isothiocyanate (3.32 ml, 0.025 mole), n-hexanoic acid
hydrazide (3.25 g, 0.025 mole), and sodium ethoxide [from
35 sodium (1.15 g, 0.05 mole) in ethanol (40 ml)] gave the
product after removing the ethanol under vacuum, diluting
the residue with water and acidifying with 10%
hydrochloric acid. The crude product was recrystallized

- 1 twice from ethanol/hexane to give a solid with melting
point 126-127°C (4.39 g, 67%).

Example 35

5

3-Mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole

Following the method of Example 18, benzyl
isothiocyanate (3.32 ml, 0.025 mole), n-octanoic acid
10 hydrazide (3.96 g, 0.025 mole), and sodium ethoxide [from
sodium (1.15 g, 0.05 mole) in ethanol (50 ml)] gave the
product after acidifying with 10% hydrochloric acid. The
crude product was recrystallized from ethanol to give a
solid with melting point 120-121°C (5.84 g, 81%).

15

Example 36

3-Mercapto-4-benzyl-5-n-nonyl-1,2,4-triazole

20 Following the method of Example 18, benzyl
isothiocyanate (3.32 ml, 0.025 mole), n-decanoic acid
hydrazide (4.66 g, 0.025 mole), and sodium ethoxide [from
sodium (1.15 g, 0.05 mole) in ethanol (50 ml)] gave the
product after acidifying with 10% hydrochloric acid. The
25 crude product was recrystallized twice from ethanol to
give a solid with melting point 116-117°C (6.33 g, 80%).

Example 37

30 3-Mercapto-4-benzyl-5-cyclohexyl-1,2,4-triazole

Following the method of Example 18, benzyl
isothiocyanate (3.32 ml, 0.025 mole), cyclohexane
carboxylic acid hydrazide (3.59 g, 0.0252 mole), and
35 sodium ethoxide [from sodium (1.15 g, 0.05 mole) in
ethanol (50 ml)] gave the product after removing the
ethanol under vacuum, diluting the residue with water and
acidifying with 10% hydrochloric acid. The crude product

- 1 was recrystallized three times from ethanol to give a solid with melting point 171-172°C (3.28 g, 49%).

Example 38

5

3-Benzylthiosemicarbazide

- Benzyl isothiocyanate (6.54 g, 0.0438 mole) was added to a solution of hydrazine monohydrate (3.32 g, 10 0.0657 mole) in ethanol (50 ml) and the solution was heated under reflux for 2 hours. The reaction mixture was cooled in ice and the product was filtered and washed with cold ethanol/hexane to give a solid with melting point 126-127°C (5.50 g, 69%).

15

Example 39

1-t-Butylcarbonyl-4-benzylthiosemicarbazide

- 20 Trimethylacetyl chloride (3.7 ml, 0.03 mole) was added dropwise to a solution of 4-benzylthiosemicarbazide (5.44 g, 0.03 mole) in dry pyridine (40 ml) at -10°C. The reaction was stirred at -10°C for 15 minutes and at 25°C for 4.75 hours. The reaction mixture was poured into 25 crushed ice and the product was filtered and recrystallized from ethanol to give a solid with melting point 143.5-144.5°C (6.19 g, 78%).

Example 40

30

3-Mercapto-4-benzyl-5-t-butyl-1,2,4-triazole

- Following the method of Example 2, 1-t-butylcarbonyl-4-benzylthiosemicarbazide (5.0 g, 0.019 mole) and 35 sodium ethoxide [from sodium (0.866 g, 0.0377 mole) in ethanol (70 ml)] gave the product which was recrystallized from ethanol with melting point 200-201°C (2.79 g, 60%).

1

Example 413-Mercapto-4,5-dibenzyl-1,2,4-triazole

5

Following the method of Example 18, benzyl isothiocyanate (3.66 ml, 0.0276 mole), phenylacetic acid hydrazide (4.14 g, 0.0276 mole), and sodium ethoxide [from sodium (1.27 g, 0.0552 mole) in ethanol (40 ml)] gave the product after removing the ethanol under vacuum, diluting the residue with water and acidifying with 10% hydrochloric acid. The crude product was recrystallized twice from ethanol to give a solid with melting point 169-170°C (4.09 g, 53%).

15

Example 421-Phenylpropionyl-4-benzylthiosemicarbazide

Hydrocinnamoyl chloride (2.25 ml, 0.0152 mole) was added dropwise to a solution of 4-benzylthiosemicarbazide (2.75 g, 0.0152 mole) in dry pyridine (25 ml) at -10°C. The reaction was stirred at -10°C for 10 minutes and then at 25°C. An additional 0.5 ml of hydrocinnamoyl chloride was added and the reaction mixture was stirred for 17 hours. Another 1.0 ml of the acid chloride was added and the reaction mixture was poured into crushed ice and the product was filtered and triturated twice with ethanol to give a solid with melting point 178-180°C (3.48 g, 73%).

30

Example 433-Mercapto-4-benzyl-5-phenethyl-1,2,4-triazole

35

Following the method of Example 2, 1-phenylpropionyl-4-benzylthiosemicarbazide (3.41 g, 0.0109 mole) and sodium ethoxide [from sodium (0.50 g, 0.0218 mole) in ethanol (50 ml)] gave the product which

SUBSTITUTE SHEET

- 1 was recrystallized from ethanol, then ethyl acetate and finally ethyl acetate/ethanol with melting point 189-190°C (1.85 g, 60%).

5 Example 44

3-Mercapto-4-benzyl-5-(4-methoxyphenyl)-1,2,4-triazole

- Following the method of Example 18, benzyl
10 isothiocyanate (3.32 ml, 0.025 mole), 4-methoxybenzhydrazide (4.14 g, 0.025 mole), and sodium ethoxide [from sodium (1.15 g, 0.05 mole) in ethanol (80 ml)] gave the product after removing the ethanol under vacuum, diluting the residue with water and acidifying with 10%
15 hydrochloric acid. The crude product was recrystallized twice from ethanol to give a solid with melting point 202-203°C (4.16 g, 56%).

Example 45

- 20 3-Mercapto-4-benzyl-5-(3,4,5-trimethoxyphenyl)-1,2,4-triazole

- Following the method of Example 18, benzyl
25 isothiocyanate (3.32 ml, 0.025 mole), 3,4,5-trimethoxybenzhydrazide (5.66 g, 0.025 mole), and sodium ethoxide [from sodium (1.15 g, 0.05 mole) in ethanol (50 ml)] gave the product after removing the ethanol under vacuum, diluting the residue with water and acidifying with 10%
30 hydrochloric acid. The crude product was recrystallized twice from ethanol, dissolved in dilute sodium hydroxide, filtered and reacidified with 10% hydrochloric acid. The solid was filtered and recrystallized twice from ethanol to give a solid with melting point 177-178°C (3.39 g, 38%).

35

1

Example 463-Mercapto-4-benzyl-5-(4-chlorophenyl)-1,2,4-triazole

5

Following the method of Example 18, benzyl isothiocyanate (3.32 ml, 0.025 mole), 4-chloro-benzhydrazide (4.26 g, 0.025 mole), and sodium ethoxide [from sodium (1.15 g, 0.05 mole) in ethanol (80 ml)] gave the product after removing the ethanol under vacuum, diluting the residue with water and acidifying with 10% hydrochloric acid. The crude product was recrystallized from ethanol to give a solid with melting point 197-198°C (4.58 g, 61%).

15

Example 473-Mercapto-4-benzyl-5-(4-bromophenyl)-1,2,4-triazole

Following the method of Example 18, benzyl isothiocyanate (1.99 ml, 0.015 mole), 4-bromobenzhydrazide (3.23 g, 0.015 mole), and sodium ethoxide [from sodium (0.690 g, 0.03 mole) in ethanol (25 ml)] gave the product after removing the ethanol under vacuum, diluting the residue with water and acidifying with 10% hydrochloric acid. The crude product was recrystallized twice from ethanol to give a solid with melting point 213-214°C (2.81 g, 54%).

30

Example 483-Mercapto-4-benzyl-5-(3-bromophenyl)-1,2,4-triazole

Following the method of Example 18, benzyl isothiocyanate (1.99 ml, 0.015 mole), 3-bromobenzhydrazide (3.23 g, 0.015 mole), and sodium ethoxide [from sodium (0.690 g, 0.03 mole) in ethanol (25 ml)] gave the product after removing the ethanol under vacuum, diluting the residue with water and acidifying with 10% hydrochloric

SUBSTITUTE SHEET

1 acid. The crude product was recrystallized twice from
ethanol to give a solid with melting point 176-177°C (3.68
g, 71%).

5 The following lettered examples describe
preparation of selected compounds used in preparing
compounds of structure (I).

Example A

10

3,5-Difluorobenzaldehyde

A mixture of 3,5-difluorobenzonitrile (15.0 g,
0.11 mole) and Raney catalyst powder (15 g) in 90% formic
15 acid (150 ml) was stirred under reflux for 2.5 hours and
the catalyst was filtered and washed with hot water and
hexane. The hexane layer was separated and the aqueous
solution was extracted two more times with hexane. The
combined hexane extracts were washed with water and brine,
20 dried and the solvent was removed to give an oil (8.51 g,
56%).

Example B

25 3,5-Difluorocinnamic acid

A mixture of 3,5-difluorobenzaldehyde (8.5 g,
0.0598 mole), malonic acid (9.29 g, 0.0893 mole), pyridine
(3.2 ml) and piperidine (0.15 ml) was heated for 1.5 hours
30 at 100°C and 3 hours at 150°C. The reaction mixture was
cooled to room temperature and the resulting solid was
trituated with 10% hydrochloric acid and filtered. The
product then was trituated with ethanol, filtered and
dried to give a solid with melting point 199-201°C (8.12
35 g, 74%).

1

Example C3-(3,5-Difluorophenyl)propionic acid

5 A suspension of 10% palladium on carbon (1.5 g) in ethyl acetate was added to a solution of 3,5-difluorocinnamic acid (8.12 g, 0.0441 mole) in tetrahydrofuran (100 ml) and the mixture was shaken under a hydrogen atmosphere (50 pounds) for 1 hour. The catalyst was filtered and the solvent was removed under vacuum to give the product as a solid (8.25 g, 100%).

Example D15 3-(3,5-Difluorophenyl)propanol

A solution of 1M borane (97 ml, 0.097 mole) in tetrahydrofuran was added to a solution of 3-(3,5-difluorophenyl)propionic acid (8.21 g, 0.0441 mole) in tetrahydrofuran (75 ml) at 0°C and the solution was stirred at 25° for 17 hours. The reaction mixture was cooled in ice, and methanol was slowly added to destroy excess borane. The solvent was removed under vacuum and the residue was dissolved in ether and the mixture was filtered. The ether solution was washed with water and brine and then dried over sodium sulfate. The solvent was removed to give the product as an oil (8.37 g, 100%).

Example E

30

3-(3,5-Difluorophenyl)propyl azide

p-Toluenesulfonyl chloride (18.5 g, 0.0972 mole) was added to a solution of 3-(3,5-difluorophenyl)propanol (8.37 g, 0.0486 mole) in pyridine (75 ml) at 0°C. The reaction mixture was stirred at 0°C for 20 minutes and at 25°C for 2 hours and then kept at 4°C for 17 hours. The mixture was poured into an ice/water mixture and extracted

1 with 3 portions of ether. The ether solution was washed
with several portions of cold 1N hydrochloric acid
followed by water and then brine. The solution was dried
over sodium sulfate and the solvent was removed to give
5 the crude tosylate as an oil. The oil was taken up in
dimethylformamide (75 ml) and sodium azide (6.32 g, 0.0972
mole) was added and the mixture was stirred for 17 hours
under an argon atmosphere. The reaction mixture was
quenched in ice water and then extracted with 3 portions
10 of ethyl acetate. The solution was washed with cold 1N
hydrochloric acid followed by water and brine and then
dried over sodium sulfate. The solvent was removed under
vacuum and the resulting oil was dissolved in hexane/ethyl
acetate (9:1) and purified by flash silica chromatography
15 to give the product as an oil (6.01 g, 63%).

Example F

3-(3,5-Difluorophenyl)propylamine

20

A solution of 3-(3,5-difluorophenyl)propyl azide
in methanol (75 ml) and Raney nickel was shaken in a
hydrogen atmosphere (50 pounds) for 5.5 hours. The
catalyst was filtered and the solvent was removed under
25 vacuum to give the product as an oil (4.94 g, 98%).

Example G

3,5-Difluoro-4-methoxybenzaldehyde

30

A mixture of 3,5-difluoro-4-methoxybenzonitrile
(18.0 g, 0.106 mole) and Raney catalyst powder (18 g) in
90% formic acid (180 ml) was stirred under reflux for 3
hours and the catalyst filtered and washed with hot water
35 and hexane. The hexane layer was separated and the
aqueous solution was extracted an additional four times
with hexane. The combined hexane extracts were washed
with water and brine, dried and the solvent was removed
to give a solid (16.5 g, 90%).

SUBSTITUTE SHEET

1

Example H3,5-Difluoro-4-methoxycinnamic acid

5 A mixture of 3,5-difluoro-4-methoxybenzaldehyde (16.5 g, 0.0959 mole), malonic acid (15.0 g, 0.144 mole), pyridine (5.3 ml, 0.065 mole) and piperidine (0.26 ml, 2.6 mmole) was heated for 1 hour at 100°C and 4 hours at 150°C. The reaction mixture was cooled to room
10 temperature and the resulting solid was triturated with 10% hydrochloric acid and filtered. The product was then triturated with ethanol, filtered and dried to give a solid with melting point 211-213°C (17.3 g, 84%).

15

Example I3-(3,5-Difluoro-4-methoxyphenyl)propionic acid

A suspension of 10% palladium on carbon (1.5 g)
20 in ethyl acetate was added to a solution of 3,5-difluoro-4-methoxycinnamic acid (17.3 g, 0.0808 mole) in tetrahydrofuran (150 ml) and the mixture was shaken under a hydrogen atmosphere (50 pounds) for 1 hour. The catalyst was filtered and the solvent was removed under
25 vacuum to give the product as a solid (17.5 g, 100%).

Example J30 3-(3,5-Difluoro-4-methoxyphenyl)propanol

A solution of 1M borane (178 ml, 0.178 mole) in tetrahydrofuran was added to a solution of 3-(3,5-difluoro-4-methoxyphenyl)propionic acid (17.5 g, 0.0808 mole) in
35 tetrahydrofuran (125 ml) at 0°C and the solution was stirred at 25° for 17 hours. The reaction mixture was cooled in ice and methanol was slowly added to destroy excess borane. The solvent was removed under vacuum and

SUBSTITUTE SHEET

1 the residue was dissolved in ether and the mixture was
filtered. The ether solution was washed with water and
brine and then dried over sodium sulfate. The solvent was
removed to give the product as an oil (16.7 g, 100%).

5

Example K

3-(3,5-Difluorophenyl)propyl azide

10 p-Toluenesulfonyl chloride (17.9 g, 0.0939 mole)
was added to a solution of 3-(3,5-difluoro-4-methoxy-
phenyl)propanol (9.49 g, 0.0469 mole) in pyridine (120 ml)
at 0°C. The reaction mixture was stirred at 0°C for 6
hours and then kept at -10°C for 2 days. The mixture was
15 poured into an ice/water mixture and extracted with 3
portions of ether. The ether solution was washed with
several portions of cold 1N hydrochloric acid followed by
water and then brine. The solution was dried over sodium
sulfate and the solvent was removed to give the crude
20 tosylate as an oil. The oil was taken up in
dimethylformamide (80 ml) and sodium azide (6.10 g, 0.0939
mole) was added and the mixture was stirred for 17 hours
under an argon atmosphere. The reaction mixture was
quenched in ice water and then extracted with 3 portions
25 of ethyl acetate. The solution was washed with water and
brine and then dried over sodium sulfate. The solvent was
removed under vacuum to give the product as an oil (11.3
g, 100%).

30

Example L

3-(3,5-Difluoro-4-methoxyphenyl)propylamine

A solution of 3-(3,5-difluoro-4-methoxyphenyl)-
35 propyl azide in methanol (110 ml) and Raney nickel was
shaken in a hydrogen atmosphere (50 pounds) for 3 hours.
The catalyst was filtered and the solvent was removed
under vacuum to give the product as an oil (9.01 g, 95%).

SUBSTITUTE SHEET

1

Example Mn-Hexanoic acid hydrazide

5

A solution of ethyl hexanoate (14.4 g, 0.10 mole) and hydrazine monohydrate (7.35 ml, 0.15 mole) in ethanol (75 ml) was heated under reflux for 17 hours. The solvent was removed under vacuum and the residual oil was triturated with hexane with ice cooling. The product was
10 filtered and recrystallized from ether to give a solid with melting point 70.5-71.5°C (6.10 g, 47%).

Example N

15

n-Octanoic acid hydrazide

Following the method of Example M, ethyl octanoate (17.2 g, 0.10 mole) and hydrazine monohydrate (7.35 ml, 0.15 mole) in ethanol (75 ml) gave the product
20 by triturating the residual oil with ether to give a solid with melting point 85-87°C (5.50 g, 35%).

Example O

25

n-Decanoic acid hydrazide

Following the method of Example M ethyl decanoate (20.0 g, 0.10 mole) and hydrazine monohydrate (7.25 ml, 0.15 mole) in ethanol (75 ml) gave the product
30 by removing about half the solvent under vacuum, cooling in ice and filtering off the solid. The crude product was recrystallized from ethanol/hexane to give a solid with melting point 95-96.5°C (8.56 g, 46%).

35

SUBSTITUTE SHEET

Example P

Cyclohexane carboxylic acid hydrazide

5 Following the method of Example M, methyl
cyclohexane carboxylate (14.2 g, 0.10 mole) and hydrazine
monohydrate (7.25 ml, 0.15 mole) in ethanol (100 ml) gave
the product by triturating the residual oil with
ether/hexane and recrystallizing with ethyl acetate/hexane
10 to give a solid with melting point 149-153°C (3.59 g, 25%).

Example 0

Phenylacetic acid hydrazide

15 Following the method of Example M, ethyl phenylacetate (16.4 g, 0.10 mole) and hydrazine monohydrate (7.35 ml, 0.15 mole) in ethanol (200 ml) gave the product by triturating the residual oil with ether and
20 recrystallizing twice from ethanol to give a solid with melting point 110-112°C (4.14 g, 28%).

Example R

25 3-Bromobenzoic acid hydrazide

Following the method of Example M, ethyl-3-bromobenzoate (22.9 g, 0.10 mole) and hydrazine monohydrate (7.35 ml 0.15 mole) in ethanol (75 ml) gave the product by diluting the reaction mixture with ether and filtering off the product to give a solid with melting point 153-154.5°C (14.7 g, 68%).

Example 49

35 An oral dosage form for administering the presently invented compounds is produced by screening, mixing, and filling into hard gelatin capsules the ingredients in the proportions shown in Table II, below.

1

Table II

	<u>Ingredients</u>	<u>Amounts</u>
5	3-Mercapto-4-(3,5-difluorobenzyl)-5-phenyl-1,2,4-triazole	50 mg
	magnesium stearate	5 mg
	lactose	75 mg

10

Example 50

The sucrose, calcium sulfate dihydrate, and structure (I) compound shown in Table III below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

20

Table III

	<u>Ingredients</u>	<u>Amounts</u>
25	3-Mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-triazole	100 mg
	calcium sulfate dihydrate	150 mg
	sucrose	20 mg
	Starch	10 mg
	talc	5 mg
30	stearic acid	3 mg

Example 51

3-Mercapto-4,5-dibenzyl-1,2,4-triazole, 75 mg, is dispersed in 25 ml of normal saline to prepare an injectable preparation.

SUBSTITUTE SHEET

1 Contemplated equivalents of compounds of
structure (I) are compounds that upon administration to
mammals, including humans, are metabolized to compounds of
structure (I) or metabolized to any active metabolites of
5 compounds of structure (I) at a sufficient rate and in
sufficient amounts to produce the physiological activity
of compounds of structure (I). Such compounds also would
be included in the invented pharmaceutical compositions
and used in the invented methods.

10 While the preferred embodiments of the invention
are illustrated by the above, the invention is not limited
to the precise instructions herein disclosed and that the
right to all modifications coming within the scope of the
15 following claims is reserved.

20

25

30

35

SUBSTITUTE SHEET


Claims

1

1. A compound of structure (I)

5

10



in which,

n is 0 to 5;

15 X^1 to X^5 are any accessible combination of hydrogen,
 halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano,
 nitro, $SONH_2$, SO_2NH_2 , SO_2CH_3 ,
 SO_2CH_2F , SO_2CHF_2 , SO_2CF_3 , CF_3 ,
 CHO, OH, CH_2OH , CO_2H , or $CO_2C_pH_{2p+1}$
 20 wherein p is 1 to 4;

R^1 is phenyl substituted by X^1 to X^5 , C_{1-4} alkyl,
 C_{3-6} cycloalkyl, or an aryl C_{1-4} alkyl group
 substituted by X^1 to X^5 ;

25

R^2 is hydrogen, C_{1-4} alkyl or $(CH_2)_m-CO_2R^3$;

m is 0 to 5; and

30 R^3 is H or C_{1-4} alkyl; or

a pharmaceutically acceptable salt thereof provided that

35

(i) when n is 0, R^2 is hydrogen and X^1 to
 X^5 are hydrogen, R^1 is other than
 phenyl or phenyl substituted by OH,
 C_{1-6} alkoxy, halogen;

- 1 (ii) when n is 0, R^2 is hydrogen, X^1 is
C₁₋₆alkyl or C₁₋₆alkoxy and X^2 to
5 X^5 are hydrogen, R^1 is other than
phenyl or phenyl substituted by
C₁₋₆alkyl, C₁₋₆alkoxy, hydroxy or
halogen;
- 10 (iii) when n is 0, R^2 is hydrogen, X^2 is
C₁₋₆alkyl or halogen and X^1 and X^3
to X^5 are hydrogen, R^1 is other than
phenyl or phenyl substituted by
C₁₋₆alkyl, C₁₋₆alkoxy, hydroxy or
halogen;
- 15 (iv) when n is 0, R^2 is hydrogen, X^1 , X^2
and X^4 , X^5 are hydrogen and X^3 is
C₁₋₆alkyl, halogen or C₁₋₆alkoxy, R^1
is other than phenyl or phenyl substituted
by C₁₋₆alkoxy, hydroxy, halogen or nitro.
- 20 (v) when n is 0, R^2 is hydrogen, X^4 and
 X^5 are hydrogen, X^1 and X^2 are each
hydrogen or C₁₋₆alkyl and X^3 is
C₁₋₆alkyl, R^1 is other than a phenyl
25 group substituted by three C₁₋₆alkoxy
groups;
- 30 (iv) when n is 0, R^2 is hydrogen, X^1 , X^4
and X^5 are hydrogen and X^2 and X^3
are halogen, R^1 is other than a phenyl
group substituted by hydroxy or halogen;
and
- 35 (vii) when n is 1, R^2 is hydrogen and X^1 to
 X^5 are all hydrogen, R^1 is other than
phenyl or a phenyl group substituted by
C₁₋₆alkyl, C₁₋₆alkoxy, halogen or
NO₂.

SUBSTITUTE SHEET

- 1 2. A compound of claim 1 in which n is 0 or 1.
3. A compound of claim 2 in which one or two
of X^1 to X^5 is halogen.
- 5 4. A compound of claim 2 in which X^2 or
 X^4 is halogen or X^4 and X^2 are halogen.
5. A compound of claim 2 in which X^2 and
10 X^4 are halogen and X^3 is C_{1-6} alkoxy.
6. A compound of claim 2 that is
3-mercapto-4-(3,5-difluorobenzyl)-5-phenyl-1,2,4-triazole.
- 15 7. A compound of claim 1 that is:
- 3-mercapto-4-(3,5-difluoro-4-methoxybenzyl)-5-
phenyl-1,2,4-triazole,
- 20 3-mercapto-4-(3,5-difluoro-4-hydroxybenzyl)-5-
phenyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-
triazole,
- 25 3-mercapto-4-(3,5-difluorobenzyl)-5-(4-t-butyl-
phenyl)-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-phenyl-1,2,4-triazole,
- 30 3-mercapto-4-methyl-5-phenyl-1,2,4-triazole,
3-mercapto-4-phenyl-5-(4-t-butylphenyl)-1,2,4-
triazole,
- 35 3-mercapto-4-(4-chlorophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,
- 3-mercapto-4-(4-bromophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

- 1 3-mercapto-4-(4-fluorophenyl)-5-(4-t-butylphenyl)-
1,2,-4-triazole,
- 5 3-mercapto-4-(3-phenylpropyl)-5-(4-t-butylphenyl)-
1,2,-4-triazole,
- 3-mercapto-4-(3-phenylethyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,
- 10 3-mercapto-4-[3-(3,5-difluorophenyl)propyl]-5-(4-
t-butylphenyl)-1,2,4-triazole,
- 3-mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)-
propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 15 3-mercapto-4-[3-(3,5-difluoro-4-hydroxyphenyl)-
propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-methyl-1,2,4-triazole,-
- 20 3-mercapto-4-benzyl-5-n-propyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-pentyl-1,2,4-triazole,
- 25 3-mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-nonyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-cyclohexyl-1,2,4-triazole,
- 30 3-mercapto-4-benzyl-5-t-butyl-1,2,4-triazole,
- 3-mercapto-4,5-dibenzyl-1,2,4-triazole,
- 35 3-mercapto-4-benzyl-5-phenethyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-(4-methoxyphenyl)-1,2,4-
triazole,


SUBSTITUTE SHEET

- 1 3-mercapto-4-benzyl-5-(3,4,5-trimethoxyphenyl)-
1,2,4-triazole,
- 5 3-mercapto-4-benzyl-5-(4-chlorophenyl)-1,2,4-
triazole,
- 3-mercapto-4-benzyl-5-(4-bromophenyl)-1,2,4-
triazole, or
- 10 3-mercapto-4-benzyl-5-(3-bromophenyl)-1,2,4-
triazole.

8. A pharmaceutical composition comprising a
compound of structure (Ib)

15

20



in which,

n is 0 to 5;

25

X^1 to X^5 are any accessible combination of hydrogen,
halogen, C_{1-6} alkyl, C_{1-6} alkoxy, SO_2CH_3 ,
 SO_2CH_2F , SO_2CHF_2 , SO_2CF_3 , CF_3 ,
CHO, OH, CH_2OH , CO_2H , or $CO_2C_pH_{2p+1}$
30 wherein p is 1 to 4;

30

R^1 is phenyl substituted by X^1 to X^5 , C_{1-4} alkyl,
branched chain alkyl, C_{3-6} cycloalkyl, or a
 C_{1-4} alkyl or a C_{1-4} alkyl substituted by X^1
35 to X^5 ;

35

R^2 is hydrogen, C_{1-4} alkyl, or $(CH_2)_m-CO_2R^3$; or
a pharmaceutically acceptable salt thereof, in association
with a pharmaceutically acceptable carrier.

SUBSTITUTE SHEET

1 9. A composition of claim 8 in which the
compound is 3-mercapto-4-[3,5-difluorobenzyl]-5-phenyl-
1,2,4-triazole.

5 10. A composition of claim 8 in which the
compound is:

3-mercapto-4-(3,5-difluoro-4-hydroxybenzyl)-5-
phenyl-1,2,4-triazole,

10 3-mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-
triazole,

3-mercapto-4-(3,5-difluorobenzyl)-5-(4-t-butyl-
phenyl)-1,2,4-triazole,

15 3-mercapto-4-benzyl-5-phenyl-1,2,4-triazole,

3-mercapto-4-methyl-5-phenyl-1,2,4-triazole,

20 3-mercapto-4-phenyl-5-(4-t-butylphenyl)-1,2,4-
triazole,

3-mercapto-4-(4-chlorophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

25 3-mercapto-4-(4-bromophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

3-mercapto-4-(4-fluorophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

30 3-mercapto-4-(3-phenylpropyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

3-mercapto-4-(3-phenylethyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

35 3-mercapto-4-[3-(3,5-difluorophenyl)propyl]-5-(4-
t-butylphenyl)-1,2,4-triazole,

- 1 3-mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)-
propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 5 3-mercapto-4-[3-(3,5-difluoro-4-hydroxyphenyl)-
propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-methyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-propyl-1,2,4-triazole,
- 10 3-mercapto-4-benzyl-5-n-pentyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole,
- 15 3-mercapto-4-benzyl-5-n-nonyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-cyclohexyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-t-butyl-1,2,4-triazole,
- 20 3-mercapto-4,5-dibenzyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-phenethyl-1,2,4-triazole,
- 25 3-mercapto-4-benzyl-5-(4-methoxyphenyl)-1,2,4-
triazole,
- 3-mercapto-4-benzyl-5-(3,4,5-trimethoxyphenyl)-
1,2,4- triazole,
- 30 3-mercapto-4-benzyl-5-(4-chlorophenyl)-1,2,4-
triazole,
- 3-mercapto-4-benzyl-5-(4-bromophenyl)-1,2,4-
triazole, or
- 35 3-mercapto-4-benzyl-5-(3-bromophenyl)-1,2,4-
triazole.

1 11. A method of inhibiting DBH activity which
comprises administering to a mammal an effective amount of
a claim 8, structure (Ib) compound.

5 12. A method of claim 11 in which the compound
is 3-mercapto-4-(3,5-difluorobenzyl)-5-phenyl-
1,2,4, triazole.

10 13. A method of claim 11 in which the compound
is:

3-mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-
triazole,

15 3-mercapto-4-(3,5-difluorobenzyl)-5-(4-t-butyl-
phenyl)-1,2,4-triazole,

3-mercapto-4-benzyl-5-phenyl-1,2,4-triazole,

20 3-mercapto-4-methyl-5-phenyl-1,2,4-triazole,

3-mercapto-4-phenyl-5-(4-t-butylphenyl)-1,2,4-
triazole,

25 3-mercapto-4-(4-chlorophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

3-mercapto-4-(4-bromophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

30 3-mercapto-4-(4-fluorophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

35 3-mercapto-4-(3-phenylpropyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

3-mercapto-4-(3-phenylethyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

SUBSTITUTE SHEET

- 1 3-mercapto-4-[3-(3,5-difluorophenyl)propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 5 3-mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 3-mercapto-4-[3-(3,5-difluoro-4-hydroxyphenyl)propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 10 3-mercapto-4-benzyl-5-methyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-propyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-pentyl-1,2,4-triazole,
- 15 3-mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-nonyl-1,2,4-triazole,
- 20 3-mercapto-4-benzyl-5-cyclohexyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-t-butyl-1,2,4-triazole,
- 3-mercapto-4,5-dibenzyl-1,2,4-triazole,
- 25 3-mercapto-4-benzyl-5-phenethyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-(4-methoxyphenyl)-1,2,4-triazole,
- 30 3-mercapto-4-benzyl-5-(3,4,5-trimethoxyphenyl)-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-(4-chlorophenyl)-1,2,4-triazole,
- 35 3-mercapto-4-benzyl-5-(4-bromophenyl)-1,2,4-triazole, or

SUBSTITUTE SHEET

1 3-mercapto-4-benzyl-5-(3-bromophenyl)-1,2,4-
 triazole.

14. A method of treatment to produce lower
5 blood pressure in a mammal that comprises administering to
 a mammal an effective amount of a compound of claim 8
 structure (Ib).

15. A method of claim 14 in which the compound
10 administered is 3-mercapto-4-(3,5-difluorobenzyl)-5-phenyl-
 1,2,4-triazole.

16. A method of claim 14 in which the compound
is
15 3-mercapto-4-benzyl-5-(4-t-butylphenyl)-1,2,4-
 triazole,

20 3-mercapto-4-(3,5-difluorobenzyl)-5-(4-t-butyl-
 phenyl)-1,2,4-triazole,

3-mercapto-4-benzyl-5-phenyl-1,2,4-triazole,

25 3-mercapto-4-methyl-5-phenyl-1,2,4-triazole,

3-mercapto-4-phenyl-5-(4-t-butylphenyl)-1,2,4-
triazole,

30 3-mercapto-4-(4-chlorophenyl)-5-(4-t-butylphenyl)-
 1,2,4-triazole,

3-mercapto-4-(4-bromophenyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

35 3-mercapto-4-(4-fluorophenyl)-5-(4-t-butylphenyl)-
 1,2,4-triazole,

3-mercapto-4-(3-phenylpropyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,

SUBSTITUTE SHEET


- 1 3-mercapto-4-(3-phenylethyl)-5-(4-t-butylphenyl)-
1,2,4-triazole,
- 5 3-mercapto-4-[3-(3,5-difluorophenyl)propyl]-5-(4-
t-butylphenyl)-1,2,4-triazole,
- 3-mercapto-4-[3-(3,5-difluoro-4-methoxyphenyl)-
propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 10 3-mercapto-4-[3-(3,5-difluoro-4-hydroxyphenyl)-
propyl]-5-(4-t-butylphenyl)-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-methyl-1,2,4-triazole,
- 15 3-mercapto-4-benzyl-5-n-propyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-pentyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-n-heptyl-1,2,4-triazole,
- 20 3-mercapto-4-benzyl-5-n-nonyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-cyclohexyl-1,2,4-triazole,
- 25 3-mercapto-4-benzyl-5-t-butyl-1,2,4-triazole,
- 3-mercapto-4,5-dibenzyl-1,2,4-triazole,
- 3-mercapto-4-benzyl-5-phenethyl-1,2,4-triazole,
- 30 3-mercapto-4-benzyl-5-(4-methoxyphenyl)-1,2,4-
triazole,
- 3-mercapto-4-benzyl-5-(3,4,5-trimethoxyphenyl)-
1,2,4-triazole,
- 35 3-mercapto-4-benzyl-5-(4-chlorophenyl)-1,2,4-
triazole,

SUBSTITUTE SHEET

1 3-mercapto-4-benzyl-5-(4-bromophenyl)-1,2,4-
 triazole, or

5 3-mercapto-4-benzyl-5-(3-bromophenyl)-1,2,4-
 triazole.

17. A compound of structure (II)



15 in which

x^1 to x^5 are any accessible combination of hydrogen,
 halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano,
 nitro, $SONH_2$, SO_2NH_2 , SO_2CH_3 ,
 20 SO_2CH_2F , SO_2CHF_2 , SO_2CF_3 , CF_3 ,
 CHO, CH_2OC_{1-6} alkyl, or CO_2C_{1-6} alkyl;
 and n and R_1 are as described for structure (I).

25


30

35

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/04578

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(4): A61K 31/41; C07D 249/12; C07C 159/00		
U.S. Cl.: 514/384; 548/263,265; 558/412; 564/18		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	514/384; 548/263,265; 558/412; 564/18	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
STN Online Structure Search		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	US, A, 4,628,059 (FINKELSTEIN ET AL) 9 December 1986 (09.12.86). See the entire document.	1-17
Y	EP, A, 246,088 (FINKELSTEIN ET AL) 25 November 1987 (25.11.87). See the entire document.	1-16
Y	US, A, 4,082,762 (PAGET ET AL) 4 April 1978 (04.04.78). See column 2, lines 1-30.	17
Y	Chemical Abstracts, Volume 90, No. 15, issued 9 April 1979 (Columbus, Ohio, USA), A. Kh. Avetisyan, "Synthesis And Biological Properties Of 1,4-Substituted Thiosemicarbazides And 1,2,4-Triazoles," see page 637, column 2, the abstract No. 121502g. Khim.-Farm. Zh. 1978, 12 (11), 40-3 (Russ).	1-10,17
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
15 MARCH 1989 (15.03.89)	19 APR 1989	
International Searching Authority	Signature of Authorized Officer	
ISA/US	 PATRICIA L. MORRIS	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	Chemical Abstracts, Volume 96, No. 19, issued 10 May 1982 (Columbus, Ohio, USA), M. Tandon, "Synthesis And Antiinflammatory Activity Of Some New 3-(o-substituted phenyl)-4-(substituted phenyl)-5-(alkyl/alkenylthio)-1H-1,2,4-triazoles", see page 747, the abstract No. 162602g, Indian J. Chem., Section B, 1981, 20B(11), 1017-18 (Eng).	1-10
---	---	------

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ^{1,2} not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ^{1,2}, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-16, drawn to compounds, composition and method of use, classified in 514/384.

II. Claim 17, drawn to intermediates, classified in 558/412 and 564/18.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. Telephone Practice
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Chemical Abstracts, Volume 97, No. 11, issued 13 September 1982 (Columbus, Ohio, USA), M. Tandon, "A Study Of Antiinflammatory And Analgesic Activities Of Some Newer Triazoles," see page 764, column 2, the abstract No. 92207b, Pharmacol. Res. Commun. 1982, 14(4) 359-68 (Eng).	1-10
Y	Chemical Abstracts, Volume 100, No. 11, issued 12 March 1984 (Columbus, Ohio, USA), G. Puglisi, "Anti-inflammatory Activity Of Some 3-Carboxymethylthiotriazoles In Dermatological Formulations", see page 16, column 1, the abstract No. 79477a, Boll. Chim. Farm. 1983, 122(8), 374-83 (Ital).	1-10
Y	Chemical Abstracts, Volume 99, No. 5, issued 1 August 1983 (Columbus, Ohio, USA), E.G. Knish, "Synthesis, Properties And Biological Activity Of 5-(acylalkylthio)-1,2,4-triazoles", see page 521, column 2, the abstract No. 38421v, Farm. Zh. (Kiev) 1983, (2), 64-5 (Ukrain).	1-10
Y	Chemical Abstracts, Volume 95, No. 1, issued 6 July 1981 (Columbus, Ohio, USA), G. Mazzone, "Synthesis of Pharmaceutically Significant 1-aryl-4H(R)-thiosemicarbazides; The Corresponding 5-aryl-4H(R)-1,2,4-triazoline-3-thiones And Some Derivatives", see page 634, column 2, the abstract No. 6695p, Farmaco, Ed. Sci. 1981, 36(3), 181-96 (Ital).	1-10
Y	Chemical Abstracts, Volume 91, No. 1, issued 2 July 1979 (Columbus, Ohio, USA), R.K. Jaiswal, "Synthesis of 5-(3,4,5-trimethoxyphenyl)-4-(substituted aryl)-3-(hydrazinocarbonylmethylthio)-4H-1,2,4-triazoles As Possible Anti-Inflammatory Agents", see page 486, column 1, the abstract No. 5166x, J. Heterocycl Chem. 1979, 16(3), 561-5 (Eng).	1-10, 17

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Chemical Abstracts, Volume 97, No. 25, issued 20 December 1982 (Columbus, Ohio, USA), R.S. Sharma, "Synthesis Of Fungicidal 1-Aryloxyacetyl- And 1-Arylacetyl-4-Aryl Thiosemicarbazides And Related Compounds", see page 844, column 2, the abstract No. 216087j, Bokin Bobai 1982, 10(8), 341-6 (Eng).	1-10, 17
Y	Chemical Abstracts, Volume 71, No. 11, issued 15 September 1969 (Columbus, Ohio, USA), T. Vakula, "4-Arylthiosemicarbazones And Related Products. VI. S-C And N-C Annulations During The Oxidation Of Some 4-benzylthiosemicarbazones", see page 386, column 1, the abstract No. 49855n, Indian J. Chem. 1969, 7(6), 577-80 (Eng).	1-10
Y	Chemical Abstracts, Volume 102, No. 11, issued 18 March 1985 (Columbus, Ohio, USA), B. Goswami, "Synthesis And Antifungal Activities Of Some New Substituted 1,2,4-triazoles And Related Compounds", see page 569, column 2, "see page 569, column 2, the abstract No. 95585f, J. Indian Chem. Soc. 1984, 61(6), 530-3 (Eng).	1-10, 17
Y	Chemical Abstracts, Volume 102, No. 5, issued 4 February 1985 (Columbus, Ohio, USA), B.N. Goswami, "Synthesis And Antibacterial Activity Of 1-(2,4-dichlorobenzoyl)-4-substituted Thiosemicarbazides, 1,2,4-triazoles And Their Methyl Derivatives", see page 540, column 1, the abstract No. 45567f, J. Heterocycl. Chem. 1984, 21(4), 1225-9 (Eng).	1-10, 17
Y	Chemical Abstracts, Volume 103, No. 3, issued 22 July 1985 (Columbus, Ohio, USA), F. Malbec, "Derivatives Of 2,4-dihydro-1,2,4-triazole-3-thione And 2-amino-1,3,4-thiadiazole From Thiosemicarbazones Of Esters", see page 571, column 1, the abstract No. 22524w, J. Heterocycl. Chem. 1984, 21(6), 1689-98(Fr).	1-10

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Chemical Abstracts, Volume 103, No. 13, issued 30 September 1985 (Columbus, Ohio, USA), R. Milcent, "2,4-Dihydro-1,2,4-triazole-3-thiones Substituted In Positions 4 And 5, "see page 625, column 1, the abstract No. 104977k, Fr. Demand FR 2,546,887, 7 December 1984, Appl. 83/8,983, 30 May 1983.	1-10